Radiology News In Brief
This article was originally published in The Gray Sheet
Executive Summary
CT colonography criticism: The "still rather varied" clinical data on computed tomography colonography prevent the American Society of Gastrointestinal Endoscopy from recommending the procedure, according to Bret Petersen, MD, Mayo Clinic, who served as chair of ASGE's Technology Assessment Committee. In a recent release, the organization maintains that standard colonoscopy remains a more accurate diagnostic tool. Uptake of the virtual procedure has been controversial: BlueCross BlueShield's Technology Evaluation Center and a study in JAMA have found in favor of standard colonoscopy, while a study in NEJM and UK's Interventional Procedures Advisory Committee have found CT colonography's efficacy evidence to be sufficient (1"The Gray Sheet" Nov. 29, 2004, p. 11)...
You may also be interested in...
Financings In Brief
Xtent: Menlo Park, Calif.-based firm will use proceeds of $25 mil. financing led by Morgenthaler Ventures to finish development and launch its Custom Nx coronary stent - which elutes Biosensors' Biolimus A9 drug - in the European market by Q4 2006 (1"The Gray Sheet" May 31, 2004, p. 17). Xtent will commence enrollment of a 100-person clinical trial this summer to support a CE mark. The DES system is meant to treat long, diffuse lesions and multiple lesions more rapidly and accurately than currently available devices by using a delivery system that deploys a divisible stent to different parts of the vessel, thereby minimizing catheter exchange, Xtent explains. Following EU marketing, the 48-person company will begin a 1,500-subject pivotal trial to support U.S. approval, expected in 2008. President & CEO Greg Casciaro joined Xtent last September. He previously served as CEO of Healos bone graft substitute manufacturer Orquest, which J&J/DePuy acquired in 2003 (2"The Gray Sheet" Feb. 3, 2003, In Brief)...
Financings In Brief
Xtent: Menlo Park, Calif.-based firm will use proceeds of $25 mil. financing led by Morgenthaler Ventures to finish development and launch its Custom Nx coronary stent - which elutes Biosensors' Biolimus A9 drug - in the European market by Q4 2006 (1"The Gray Sheet" May 31, 2004, p. 17). Xtent will commence enrollment of a 100-person clinical trial this summer to support a CE mark. The DES system is meant to treat long, diffuse lesions and multiple lesions more rapidly and accurately than currently available devices by using a delivery system that deploys a divisible stent to different parts of the vessel, thereby minimizing catheter exchange, Xtent explains. Following EU marketing, the 48-person company will begin a 1,500-subject pivotal trial to support U.S. approval, expected in 2008. President & CEO Greg Casciaro joined Xtent last September. He previously served as CEO of Healos bone graft substitute manufacturer Orquest, which J&J/DePuy acquired in 2003 (2"The Gray Sheet" Feb. 3, 2003, In Brief)...
Virtual Colonography Mirrors Standard Procedure Sensitivity Rates – IPAC
The evidence encompassing computed tomographic (CT) colonography adequately supports use of the procedure, according to UK's Interventional Procedures Advisory Committee